Why the FDA's Real-Time Clinical Trial Announcement Is Really About Your Bathroom

I've given the "bathroom of the future" talk more times than I can count.

At conferences. On podcasts. In consulting rooms where someone is nodding politely while quietly deciding I'm either a visionary or completely unhinged. The pitch is always the same:

Your annual physical is the worst possible moment to take a health measurement.

You drove there stressed. You sat in a waiting room under fluorescent lights. A stranger in a white coat walked in, took your blood pressure under acute social pressure, asked you twelve questions in eleven minutes, and handed you a lab result from a single morning's fasting draw. That snapshot — that one freeze-frame — is what your entire health narrative gets built on.

Meanwhile your body has been talking continuously for 365 days and nobody was listening.

That's not a bug in the system. That's the architecture. And the architecture was always the problem.

I've been saying this since 2019 in Silicon Valley rooms full of people who thought I was describing science fiction. The bathroom of the future already existed conceptually — AI-driven video in your mirror tracking changes longitudinally over months. Toilet bowl sensors flagging microbiome shifts, glucose metabolites, early inflammation markers. WiFi LiDAR passively reading your vitals, your sleep stages, your nervous system state without a single thing on your wrist. Stack all of that. Run it longitudinally. Feed it a real AI.

What you get is something a 12-minute appointment structurally cannot produce: the continuous, living signal of who you actually are.

On April 28, 2026, the FDA said the same thing. In different words. About clinical trials.

And if you read it as a regulatory update, you missed everything.

The FDA announced real-time clinical trials — RTCT. Two proof-of-concept trials already running. AstraZeneca's TRAVERSE in mantle cell lymphoma at MD Anderson and UPenn. Amgen's STREAM-SCLC in small cell lung carcinoma. Live signals already validated and flowing to the agency through Paradigm Health.

Commissioner Makary said it plainly: "For 60 years, we've been conducting clinical trials in the same way, where key data signals can take years to reach the FDA."

Sixty years. And they're just now calling it a problem.

The standard clinical trial model works like this: data flows from sites to sponsors, sponsors analyze it, then it gets submitted to the FDA — often months or years after the signals first appeared. Phase 1 ends. Hiatus. Phase 2 ends. Hiatus. Phase 3. More waiting. The entire architecture assumes that delayed, batched, episodic data reporting is acceptable.

It's the annual physical. Applied to drug development.

The FDA's Chief AI Officer is running this initiative. That's the tell. This isn't a regulatory reform. It's a data infrastructure play — and the paradigm underneath it is the same one I've been building toward in digital health for the better part of a decade.

Continuous beats episodic. Longitudinal beats snapshot. Real-time signal beats delayed batch reporting.

Every time. No contest.

Here's what I want you to actually take away from this:

The same architecture error runs through every broken system in health.

Your CGM gives you continuous glucose data. Your doctor gives you a fasting draw once a year. One of those is a movie. One is a still photograph. We built clinical medicine on still photographs and then spent fifty years wondering why we keep missing things.

HRV is your nervous system's real-time credit score — a continuous read on how much load your biology can actually handle. We replaced it with a resting pulse taken under the artificial stress of a white coat exam and called it a health metric.

The bathroom of the future replaces your doctor's office not because it's more convenient but because it sees what the doctor's office structurally cannot: the signal that lives between appointments, in the ordinary moments, in the trajectory over months and years.

And now the FDA is applying the exact same logic to drug development. Watch the signal as it happens. Don't wait for the summary. Don't batch it. Don't let it sit in a sponsor's hands while a patient waits.

This is not a coincidence. This is a paradigm shift arriving at scale.

Here's the part nobody is reporting.

The early-phase trial bottleneck isn't just inefficient. It's a filter — and it doesn't filter randomly. It filters by resources. Big pharma can afford to fund the wait between phases. They can carry a program through years of hiatus because the patent-protected compound at the end justifies it.

The frontier therapies can't.

Peptides. Off-patent compounds. Novel biologics that can't be locked behind a patent wall. These are the compounds I've been tracking for years — the ones that are already doing things in clinical practice that mainstream medicine won't acknowledge yet because there's no $50M trial behind them. They sit in early-phase purgatory not because the science fails. Because the data chain is too slow and too expensive to carry them through.

Compress that bottleneck and the calculus changes. Not just for the AstraZeneca trials that are already running with nine-figure budgets behind them. For the compounds that have never had a fair shot because the infrastructure made it structurally impossible.

AlphaFold 3 already exists. Peptide printers already exist. The guy who reverse-engineered his dog's cancer, had peptides printed in Australia, and solved it — that story isn't an anomaly. It's a preview. The infrastructure that made it possible just got a formal acknowledgement from inside the agency that regulates it.

The FDA's stated goal isn't just faster reporting. It's eliminating the hiatus between trial phases entirely. Continuous trials across the full arc of development.

That's not an incremental improvement. That's a different model of how biological truth gets established.

And it's the same model I've been building the bathroom argument around for six years.

Longitudinal. Continuous. Individual-level. Real-time.

The snapshot model of medicine was always a limitation masquerading as a standard. The annual physical. The phase-gated trial. The 12-minute appointment. The quarterly lab. We built an entire health system on the least informative moments of a person's biology and then called it evidence-based medicine.

What's happening now — in your bathroom, in your CGM data, in the FDA's real-time trial architecture — is the beginning of something different. Not augmentation of the old system. Replacement of it.

I've been called early on this before. I'm comfortable with that.

The pilot program launches this summer. The RFI closes May 29.

Watch what gets built in the gap.

— Dr. Dave

Field Notes from the Edge of Performance is a dispatch from the frontier of human biology, adventure performance, and the systems that are actually worth paying attention to. If someone forwarded this to you and you want in — you know where to find it.